As part of our mission to improve the lives of children with inflammatory bowel disease, members of the Division of Gastroenterology, Hepatology and Nutrition actively pursue research, including various aspects of IBD causes and treatment. Current studies include:

Risk stratification and identification of immunogenetic and microbial markers of rapid disease progression in children with Crohn’s disease: The RISK Study  
This multicenter study will define genetic, genomic, microbial, and immune markers of disease progression in newly diagnosed pediatric Crohn’s Disease.

Characterizing the gut microbial ecosystem for diagnosis and therapy in IBD
This project will assess the composition and biomolecular activity of gut microbes in IBD patients over time.

Telehealth Enhancement of Adherence to Medication in Pediatric IBD:  The TEAM Study
This multicenter randomized controlled trial will test the efficacy of a telehealth behavioral treatment on medication adherence in children and adolescents with IBD.

Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT Study
This multicenter study will conduct a prospective clinical trial of standardized medical therapy in pediatric Ulcerative Colitis and will identify genetic, microbial, and immune predictors of response.   

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children: The ARCH Study
This multicenter study will identify predictors of response to anti-TNF therapy in children with severe Ulcerative Colitis and guide individualized drug dosing.

A Randomized, Double-Blind, Placebo-controlled, Multi-center Pragmatic Clinical Trial to Evaluate the Effectiveness of Low Dose Oral Methotrexate in Patients with Pediatric Crohn’s Disease Initiating Anti-TNF Therapy: The COMBINE Study
This multicenter randomized controlled trial will determine whether the addition of low dose methotrexate to anti-TNF therapy results in better outcomes for children with Crohn’s Disease.

Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease
The major goals of this study are to determine whether dietary supplementation with the 2'-Fucosyllactose prebiotic in IBD will be safe and well tolerated, while increasing levels of beneficial gut bacteria in a dose dependent manner.

Learn more about our research efforts and projects.